en Clinical پژوهشي Research <p data-end="396" data-start="144" style="text-align: justify;"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><strong data-end="158" data-start="144">Objective:</strong> Central serous chorioretinopathy (CSCR) is a common cause of central vision loss, predominantly affecting men between 20 and 60 years of age. This study aimed to evaluate the efficacy of low-dose aspirin in the treatment of acute CSCR.</span></span></p> <p data-end="964" data-start="398" style="text-align: justify;"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><strong data-end="410" data-start="398">Methods:</strong> A total of 60 patients (60 eyes) with a history of acute CSCR while on fenofibrate therapy were randomized into two groups. Group A received aspirin 100 mg orally once daily for 1 month, followed by 100 mg every other day for 5 months. Group B received no medication and served as the control group. Best-corrected visual acuity (BCVA), mean subretinal fluid vertical diameter (SFVD), optical coherence tomography (OCT), and central macular thickness (CMT) were assessed at baseline and during follow-up visits at 1 week, and at 1, 2, 3, and 6 months.</span></span></p> <p data-end="1637" data-start="966" style="text-align: justify;"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><strong data-end="978" data-start="966">Results:</strong> There were no significant differences between the two groups at baseline in terms of BCVA (P = 0.968) or SFVD (P = 0.774). Group A demonstrated significant improvement in BCVA and a significant reduction in SFVD at all follow-up intervals compared with baseline values. Compared with the control group, aspirin treatment resulted in a statistically significant improvement in BCVA (P < 0.001) and a reduction in SFVD (P < 0.001) after 6 months. Moreover, 93.3% (n = 28) of patients in Group A experienced no recurrences during the follow-up period, whereas only 60.0% (n = 18) of patients in Group B achieved complete resolution of CSCR without recurrence.</span></span></p> <p data-end="1904" data-start="1639" style="text-align: justify;"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><strong data-end="1654" data-start="1639">Conclusion:</strong> Patients treated with low-dose aspirin experienced faster visual recovery and fewer recurrences compared with untreated patients. These findings suggest that oral aspirin may be a promising therapeutic option for selected patients with acute CSCR.</span></span></p> <div style="text-align: justify;"></div> ,central serous chorioretinopathy,aspirin,acetyl salicylic acid,best corrected visual acuity (BCVA),recurrence 1 9 http://pbp.medilam.ac.ir/browse.php?a_code=A-10-668-1&slc_lang=en&sid=1 Naser Samadi dr.nasersamadi@yahoo.com 10031947532846005560 10031947532846005560 No Department of Ophthalmology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran Ghader Motarjemizadeh drkadirmurathan@gmail.com 10031947532846005561 10031947532846005561 Yes Department of Ophthalmology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran Nasim Moharmzadeh moharamzade.n@gmail.com 10031947532846005562 10031947532846005562 No Department of Ophthalmology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran